ニューロゲノミクスの市場規模、シェア、予測、動向分析：オファリング別（NGS[キット、システム]、PCR、マイクロアレイ、ソフトウェア）、用途別（研究、臨床）、エンドユーザー別 - 2031年までの世界予測

ニューロゲノミクス市場は、2024年から2031年までのCAGRが16.6%で、2031年までに46億8,000万米ドルに達すると予測されます。

広範な2次調査と1次調査、市場シナリオの詳細な分析を経て、当レポートは主要な業界促進要因、抑制要因、機会、課題の分析を提供します。

ニューロゲノミクス市場の成長は、シーケンシングのコスト低下、神経疾患の有病率の増加、疾患診断と精密医療における高度なシーケンシング技術の利用拡大、医薬品研究開発費の増加、遺伝子シーケンシングに関する規制と償還シナリオの改善、ヘルスケア支出の増加、研究活動への資金提供の増加、神経疾患の早期発見と予防に対するニーズの高まり、ニューロゲノミクス製品の技術進歩、臨床・研究用途でのシーケンシングの利用を促進する政府の取り組みなどが原動力となっています。しかし、ニューロゲノミクス製品の価格が高いこと、精密医療のためのポジティブで実用的な変異を特定できる可能性が低いこと、シーケンスベースの診断に関連する倫理的・法的問題がこの市場の成長を抑制する要因となっています。

さらに、標的治療の採用の増加、新興経済国、神経疾患に関する意識の高まりは、市場利害関係者に成長機会をもたらすと期待されています。しかし、ダイナミックな規制状況、中小規模のラボの限られた専門知識とシーケンス能力、シーケンス専門家の不足、シーケンスセットアップに必要な高額な設備投資が、ニューロゲノミクス市場の成長に影響を与える主な課題となっています。

本レポートには、4年間（2021年～2024年）における主要市場プレイヤーの製品ポートフォリオ、地域的プレゼンス、主な戦略的発展の広範な評価に基づく競合情勢が含まれています。ニューロゲノミクス市場に参入している主要企業は、Illumina, Inc.（米国）、Thermo Fisher Scientific Inc.（米国）、F. Hoffmann-La Roche Ltd（スイス）、QIAGEN N.V.（オランダ）、Agilent Technologies, Inc.（米国）、Revvity, Inc.（米国）、Pacific Biosciences of California Inc.（米国）、Danaher Corporation（米国）、Oxford Nanopore Technologies Plc.（英国）、MGI Tech Co., Ltd.（中国）です。

本レポートで調査したオファリングのうち、2024年には次世代シーケンシング（NGS）セグメントがニューロゲノミクス市場で63.9％の最大シェアを占めると予想されます。このセグメントの大きなシェアは、エンドユーザーからの次世代シーケンスソリューションに対する需要の高まり、神経学研究におけるサンプル調製用消耗品の繰り返し使用、NGSの手頃な価格の増加、およびゲノム研究の成長に起因しています。

本レポートで調査した用途のうち、2024年には研究セグメントがニューロゲノミクス市場の61.6%という大きなシェアを占めると予想されます。このセグメントの大きなシェアは、ニューロゲノミクスで使用される高度なソリューションのコストが低下していること、精密医療と創薬を推進するための製薬企業やバイオテクノロジー企業の研究開発努力が増加していること、薬理学的標的の発見、治療仮説の確認、分子標的を狙った阻害化合物の潜在的な安全性の予測に情報科学ソリューションが使用されていることに起因しています。

本レポートで調査したエンドユーザーのうち、2024年には製薬・バイオテクノロジー企業セグメントがニューロゲノミクス市場で44.6%の最大シェアを占めると予想されます。このセグメントの市場シェアが大きいのは、製薬・バイオテクノロジー企業が研究開発費を増やしていることと、神経疾患の罹患率が上昇していることが、製薬・バイオテクノロジー企業における先端製品の採用を後押ししているためです。

調査範囲：

ニューロゲノミクス市場の評価：オファリング別

• 次世代シーケンサー
  • システム
  • キット＆試薬
• DNA抽出＆増幅キット＆試薬
• ライブラリー調製&ターゲットエンリッチメントキット&試薬
• 品質管理キット＆試薬
  • その他のキット・試薬
• ポリメラーゼ連鎖反応（PCR）
  • システム
  • キット＆試薬
• マイクロアレイ
  • リーダー＆スキャナー
  • キット＆試薬
• DNA＆RNAマイクロアレイキット＆試薬
• タンパク質マイクロアレイキット＆試薬
• 組織マイクロアレイキット＆試薬
• ソフトウェア＆サービス

ニューロゲノミクス市場の評価：用途別

• 研究用途
  • ターゲット同定
  • 機能研究
  • 変異体探索
  • 転写因子結合解析
• 臨床用途

ニューロゲノミクス市場の評価：エンドユーザー別

• 製薬・バイオテクノロジー企業
• 学術・研究機関
• 病院・診断研究所

ニューロゲノミクス市場の評価：地域別

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • フランス
  • イタリア
  • 英国
  • スペイン
  • その他欧州（RoE）
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋（RoAPAC）
• ラテンアメリカ
• 中東・アフリカ

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場洞察

• 概要
• 市場成長への影響要因
  • 市場力学の影響分析
  • 要因分析
• 価格分析
• 技術動向
  • ポータブルシーケンス技術の開発
• 規制分析
  • ニューロゲノミクス機器・消耗品
    • 北米
      • 米国
      • カナダ
    • 欧州
    • アジア太平洋
      • 中国
      • 日本
      • インド
    • ラテンアメリカ
    • 中東
  • ニューロゲノミクス・ソフトウェア
• ポーターのファイブフォース分析

第5章 ニューロゲノミクス市場の評価：オファリング別

• 概要
• 次世代シーケンサー（NGS）
  • キット・試薬
    • ライブラリー調製＆ターゲット濃縮キット＆試薬
    • DNA抽出および増幅キット＆試薬
    • 品質管理キット＆試薬
    • その他のキット・試薬
  • システム
• ポリメラーゼ連鎖反応（PCR）
  • キット＆試薬
  • システム
• マイクロアレイ
  • キット＆試薬
    • DNA＆RNAマイクロアレイキット＆試薬
    • タンパク質マイクロアレイキット＆試薬
    • 組織マイクロアレイキット＆試薬
  • リーダー＆スキャナー
• ソフトウェア＆サービス

第6章 ニューロゲノミクス市場の評価：用途別

• 概要
• 研究用途
  • ターゲット同定
  • 機能研究
  • 変異体探索
  • 転写因子結合解析
• 臨床用途

第7章 ニューロゲノミクス市場の評価：エンドユーザー別

• 概要
• 製薬・バイオテクノロジー企業
• 学術・研究機関
• 病院・診断研究所

第8章 ニューロゲノミクス市場の評価：地域別

• 概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他欧州（RoE）
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋（RoAPAC）
• ラテンアメリカ
• 中東・アフリカ

第9章 競合分析

• 概要
• 主要成長戦略
• 競合ベンチマーキング
• 競合ダッシュボード
  • 業界リーダー
  • 市場差別化要因
  • 先行企業
  • 新興企業
• 市場シェア分析（2023年）
  • Illumina, Inc.（U.S.）
  • Thermo Fisher Scientific Inc.（U.S.）
  • F. Hoffmann-La Roche Ltd（Switzerland）

第10章 企業プロファイル（事業概要、財務概要、製品ポートフォリオ、戦略的展開、SWOT分析*）

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Agilent Technologies, Inc.
• MGI Tech Co., Ltd.
• QIAGEN N.V.
• Revvity, Inc.
• Pacific Biosciences of California Inc.
• Danaher Corporation
• Oxford Nanopore Technologies Plc.

（注：※上位5社のSWOT分析を提供します。）

第11章 付録

LIST OF TABLES

• Table 1 Global Estimated Number of New Brain & Central Nervous System Cancer Cases, by Region, 2020 Vs. 2045
• Table 2 Sequencing Kits & Reagents/Consumables: Pricing
• Table 3 Sequencing Instruments: Product Description & Pricing
• Table 4 PCR Consumables & Instruments: Pricing
• Table 5 Portable Sequencers VS. Benchtop Sequencers: Key Differences
• Table 6 Regulatory Authorities Governing In Vitro Diagnostics & Neurogenomics Solutions, by Country/Region
• Table 7 Neurogenomics Software: Standards and Compliance Guidelines
• Table 8 Global Neurogenomics Market, by offering, 2022-2031 (USD Million)
• Table 9 Global Next-generation Sequencing (NGS) Market for Neurogenomics, by Product, 2022-2031 (USD Million)
• Table 10 Global Next-generation Sequencing (NGS) Market for Neurogenomics, by Country/Region, 2022-2031 (USD Million)
• Table 11 Global Next-generation Sequencing (NGS) Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 12 Global Next-generation Sequencing (NGS) Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
• Table 13 Global Library Preparation and Target Enrichment Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
• Table 14 Global DNA Extraction & Amplification Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
• Table 15 Global Quality Control Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
• Table 16 Global Other Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
• Table 17 Global NGS Systems Market, by Country/Region, 2022-2031 (USD Million)
• Table 18 Global Polymerase Chain Reaction (PCR) Market for Neurogenomics, by Type, 2022-2031 (USD Million)
• Table 19 Global Polymerase Chain Reaction (PCR) Market for Neurogenomics, by Country/Region, 2022-2031 (USD Million)
• Table 20 Global PCR Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
• Table 21 Global PCR Systems Market, by Country/Region, 2022-2031 (USD Million)
• Table 22 Global Microarrays Market for Neurogenomics, by Type, 2022-2031 (USD Million)
• Table 23 Global Microarrays Market for Neurogenomics, by Country/Region, 2022-2031 (USD Million)
• Table 24 Global Microarrays Kits & Reagents Market, by Type, 2022-2031 (USD MILLION)
• Table 25 Global Microarrays Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
• Table 26 Global DNA & RNA Microarray Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
• Table 27 Global Protein Microarray Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
• Table 28 Global Tissue Microarray Kits & Reagents Market, by Country/Region, 2022-2031 (USD Million)
• Table 29 Global Microarray Readers & Scanners Market, by Country/Region, 2022-2031 (USD Million)
• Table 30 Global Neurogenomics Software & Services Market, by Country/Region, 2022-2031 (USD Million)
• Table 31 Global Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 32 Global Neurogenomics Market for Research Applications, by Type, 2022-2031 (USD Million)
• Table 33 Global Neurogenomics Market for Target Identification, 2022-2031 (USD Million)
• Table 34 Global Neurogenomics Market for Functional Studies, 2022-2031 (USD MILLION)
• Table 35 Global Neurogenomics Market for Variant Discovery, 2022-2031 (USD MILLION)
• Table 36 Global Neurogenomics Market for Transcription Factor Binding Analysis, 2022-2031 (USD MILLION)
• Table 37 Global Neurogenomics Market for Clinical Applications, 2022-2031 (USD MILLION)
• Table 38 Global Neurogenomics Market, By End User, 2022-2031 (USD MILLION)
• Table 39 Pharmaceutical Spending in Major Countries
• Table 40 Global Neurogenomics Market for Pharmaceutical & Biotechnology Companies, 2022-2031 (USD Million)
• Table 41 Global Neurogenomics Market for Academic & Research Institutes, 2022-2031 (USD Million)
• Table 42 Global Neurogenomics Market for Hospitals & Diagnostic Laboratories, 2022-2031 (USD MILLION)
• Table 43 Global Neurogenomics Market, by Country/Region, 2022-2031 (USD Million)
• Table 44 North America: Neurogenomics Market, by Country, 2022-2031 (USD Million)
• Table 45 North America: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 46 North America: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 47 North America: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 48 North America: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 49 North America: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 50 North America: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 51 North America: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 52 North America: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 53 North America: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 54 U.S.: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 55 U.S.: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 56 U.S.: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 57 U.S.: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 58 U.S.: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 59 U.S.: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 60 U.S.: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 61 U.S.: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 62 U.S.: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 63 Canada: Neurogenomics Market, by offering, 2022-2031 (USD Million)
• Table 64 Canada: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 65 Canada: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 66 Canada: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 67 Canada: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 68 Canada: Neurogenomics Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 69 Canada: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 70 Canada: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 71 Canada: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 72 Europe: Neurogenomics Market, by Country/Region, 2022-2031 (USD Million)
• Table 73 Europe: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 74 Europe: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 75 Europe: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 76 Europe: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 77 Europe: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 78 Europe: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 79 Europe: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 80 Europe: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 81 Europe: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 82 Germany: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 83 Germany: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 84 Germany: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 85 Germany: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 86 Germany: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 87 Germany: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 88 Germany: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 89 Germany: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 90 Germany: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 91 France: Deaths due to Neuropsychiatric Conditions, by Sex and Age Group (2020)
• Table 92 France: Neurogenomics Market, by offering, 2022-2031 (USD Million)
• Table 93 France: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 94 France: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 95 France: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 96 France: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 97 France: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 98 France: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 99 France: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 100 France: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 101 Emergency In-Patient Hospital Admissions With a Mention Of Neurological Emergency Codes in England Among Adults Aged 18 Years and Over (2019-2020)
• Table 102 Number of Deaths Registered due to Dementia and Alzheimer's Disease in Wales and in Regions of England (2019)
• Table 103 U.K.: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 104 U.K.: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 105 U.K.: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 106 U.K.: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 107 U.K.: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 108 U.K.: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 109 U.K.: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 110 U.K.: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 111 U.K.: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 112 Italy: Deaths due to Neuropsychiatric Conditions, by Sex and Age Group (2020)
• Table 113 Italy: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 114 Italy: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 115 Italy: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 116 Italy: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 117 Italy: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 118 Italy: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 119 Italy: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 120 Italy: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 121 Italy: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 122 Spain: Deaths Due to Neuropsychiatric Conditions, by Sex and Age Group (2021)
• Table 123 Spain: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 124 Spain: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 125 Spain: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 126 Spain: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 127 Spain: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 128 Spain: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 129 Spain: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 130 Spain: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 131 Spain: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 132 RoE: Estimated Number Of New Brain And Central Nervous System Cancer Cases, by Country (2022 Vs. 2045)
• Table 133 Rest of Europe: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 134 Rest of Europe: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 135 Rest of Europe: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 136 Rest of Europe: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 137 Rest of Europe: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 138 Rest of Europe: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 139 Rest of Europe: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 140 Rest of Europe: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 141 Rest of Europe: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 142 Asia-Pacific: Neurogenomics Market, by Country/Region, 2022-2031 (USD Million)
• Table 143 Asia-Pacific: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 144 Asia-Pacific: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 145 Asia-Pacific: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 146 Asia-Pacific: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 147 Asia-Pacific: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 148 Asia-Pacific: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 149 Asia-Pacific: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 150 Asia-Pacific: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 151 Asia-Pacific: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 152 China: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 153 China: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 154 China: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 155 China: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 156 China: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 157 China: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 158 China: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 159 China: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 160 China: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 161 Japan: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 162 Japan: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 163 Japan: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 164 Japan: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 165 Japan: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 166 Japan: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 167 Japan: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 168 Japan: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 169 Japan: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 170 India: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 171 India: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 172 India: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 173 India: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 174 India: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 175 India: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 176 India: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 177 India: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 178 India: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 179 Rest of Asia-Pacific: Estimated Number of New Brain and Central Nervous System Cancer Cases, By Country (2022 VS. 2040)
• Table 180 Rest of Asia-Pacific: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 181 Rest of Asia-Pacific: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 182 Rest of Asia-Pacific: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 183 Rest of Asia-Pacific: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 184 Rest of Asia-Pacific: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 185 Rest of Asia-Pacific: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 186 Rest of Asia-Pacific: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 187 Rest of Asia-Pacific: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 188 Rest of Asia-Pacific: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 189 Latin America: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 190 Latin America: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 191 Latin America: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 192 Latin America: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 193 Latin America: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 194 Latin America: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 195 Latin America: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 196 Latin America: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 197 Latin America: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 198 Middle East & Africa: Neurogenomics Market, by Offering, 2022-2031 (USD Million)
• Table 199 Middle East & Africa: Next-generation Sequencing Market, by Type, 2022-2031 (USD Million)
• Table 200 Middle East & Africa: Next-generation Sequencing Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 201 Middle East & Africa: Polymerase Chain Reaction (PCR) Market, by Type, 2022-2031 (USD Million)
• Table 202 Middle East & Africa: Microarrays Market, by Type, 2022-2031 (USD Million)
• Table 203 Middle East & Africa: Microarray Kits & Reagents Market, by Type, 2022-2031 (USD Million)
• Table 204 Middle East & Africa: Neurogenomics Market, by Application, 2022-2031 (USD Million)
• Table 205 Middle East & Africa: Neurogenomics Market for Research Applications, by Type 2022-2031 (USD Million)
• Table 206 Middle East & Africa: Neurogenomics Market, by End User, 2022-2031 (USD Million)
• Table 207 Recent Developments, by Company, 2021-2024

LIST OF FIGURES

• Figure 1 Research Process
• Figure 2 Secondary Sources Referenced for This Study
• Figure 3 Primary Research Techniques
• Figure 4 Key Executives Interviewed
• Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
• Figure 6 Market Sizing and Growth Forecast Approach
• Figure 7 Global Neurogenomics Market, By Offering, 2024 VS. 2031 (USD Million)
• Figure 8 Global Neurogenomics Market, By Application, 2024 VS. 2031 (USD Million)
• Figure 9 Global Neurogenomics Market, By End User, 2024 VS. 2031 (USD Million)
• Figure 10 Global Neurogenomics Market: Impact Analysis of Market Drivers, Restraints, Opportunities, and Challenges (2024-2031)
• Figure 11 Genome Sequencing Costs, 2016-2024 (USD/Genome)
• Figure 12 Global Pharmaceutical R&D Expenditure, 2012-2026 (USD Billion)
• Figure 13 U.S.: Percentage Of Personalized Medicine Approvals Among Total FDA Approvals, 2015-2022 (%)
• Figure 14 U.S.: Percentage Distribution Of Older Adults With Alzheimer's Dementia, By Age Group, 2024
• Figure 15 Deaths due to Neuropsychiatric Conditions, By Country, 2020
• Figure 16 Deaths due to Parkinson's Disease, By Country, 2021
• Figure 17 Deaths due to Alzheimer's And Other Dementias, By Country, 2021
• Figure 18 USFDA Regulatory Pathways for IVD Kits
• Figure 19 Eu Regulatory Pathway - IVDR 2017/746
• Figure 20 China: Medical Device Classification And Premarket Requirements for Neurogenomics Instruments
• Figure 21 Porter's Five Forces Analysis
• Figure 22 Global Neurogenomics Market, By Offering, 2024 VS. 2031 (USD Million)
• Figure 23 Global Neurogenomics Market, By Application, 2024 VS. 2031 (USD Million)
• Figure 24 Global Neurogenomics Market, By End User, 2024 VS. 2031 (USD Million)
• Figure 25 Global Pharmaceutical R&D Expenditure, 2014-2028 (USD Billion)
• Figure 26 Global Neurogenomics Market, By Region, 2024 Vs. 2031 (USD Million)
• Figure 27 North America: Per Capita Healthcare Expenditure (2017-2022)
• Figure 28 North America: Neurogenomics Market Snapshot
• Figure 29 Europe: Pharmaceutical R&D Expenditure Annual Growth Rate (%)
• Figure 30 Europe: Neurogenomics Market Snapshot
• Figure 31 Italy: Number Of Biotechnology And Biotechnology R&D-Dedicated Firms (2014-2022)
• Figure 32 Spain: Pharmaceutical R&D Expenditure, 2018-2022 (USD Million)
• Figure 33 Asia-Pacific: Neurogenomics Market Snapshot
• Figure 34 Japan: Pharmaceutical Industry R&D Expenditure, 2017-2022 (USD Million)
• Figure 35 Number of Active Life Science Companies in Israel (2017-2022)
• Figure 36 Israel: Total Number of Life Science Industries, by Sub-Sectors (2021)
• Figure 37 Key Growth Strategies Adopted by Leading Players, 2021- 2024
• Figure 38 Global Neurogenomics Market: Competitive Benchmarking by Offering
• Figure 39 Global Neurogenomics Market: Competitive Benchmarking, by Region
• Figure 40 Competitive Dashboard: Global Neurogenomics Market
• Figure 41 Global Neurogenomics Market Share Analysis, by Key Players, 2023 (%)
• Figure 42 Illumina, Inc.: Financial Snapshot (2023)
• Figure 43 Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
• Figure 44 F. Hoffmann-La Roche Ltd.: Financial Snapshot (2023)
• Figure 45 Agilent Technologies, Inc.: Financial Snapshot (2023)
• Figure 46 MGI Tech Co., Ltd.: Financial Snapshot (2023)
• Figure 47 QIAGEN N.V: Financial Snapshot (2023)
• Figure 48 Revvity, Inc.: Financial Snapshot (2023)
• Figure 49 Pacific Biosciences Of California Inc.: Financial Snapshot (2023)
• Figure 50 Danaher Corporation: Financial Snapshot (2023)
• Figure 51 Oxford Nanopore Technologies Plc.: Financial Snapshot (2023)

Neurogenomics Market Size, Share, Forecast, & Trends Analysis by Offering (NGS [Kits {Library Prep, QC, DNA Extraction}, Systems], PCR, Microarrays {Protein, DNA, RNA, Tissue}, Software), Application (Research, Clinical), End User-Global Forecast to 2031

The neurogenomics market is projected to reach $4.68 billion by 2031 at a CAGR of 16.6% from 2024 to 2031.

Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report provides an analysis of key industry drivers, restraints, opportunities, and challenges.

The growth of the neurogenomics market is driven by the declining costs of sequencing, the increasing prevalence of neurological disorders, the growing utilization of advanced sequencing technologies in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for gene sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for the early detection & prevention of neurological disorders, technological advancements in neurogenomics products, and government initiatives promoting the use of sequencing in clinical & research applications. However, the high prices of neurogenomics products, the low chances of identifying positive, actionable mutations for precision medicine, and ethical & legal issues related to sequencing-based diagnosis are factors restraining the growth of this market.

Furthermore, the increasing adoption of targeted therapies, emerging economies, and rising awareness regarding neurological disorders are expected to generate growth opportunities for market stakeholders. However, the dynamic regulatory landscape, the limited expertise & sequencing capabilities of small & medium-sized laboratories, the shortage of sequencing professionals, and the high capital investments required for sequencing setups are major challenges impacting the growth of the neurogenomics market.

The report includes a competitive landscape based on an extensive assessment of the product portfolios, geographic presence, and key strategic developments of leading market players during the four years (2021-2024). The key players operating in the neurogenomics market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China).

Among the offerings studied in this report, in 2024, the Next-generation Sequencing (NGS) segment is expected to account for the largest share of 63.9% of the neurogenomics market. The large share of this segment is attributed to the rising demand for next-generation sequencing solutions from end users, the recurring use of sample preparation consumables in neurological research, the increasing affordability of NGS, and the growth in genomic studies.

Among the applications studied in this report, in 2024, the research segment is expected to account for the larger share of 61.6% of the neurogenomics market. The large share of this segment is attributed to the decreasing costs of advanced solutions used in neurogenomics, increasing R&D efforts of pharmaceutical and biotechnology companies for advancing precision medicine & drug discovery, and the use of informatics solutions to find pharmacological targets, confirm therapeutic hypotheses, and predict the potential safety of inhibitory compounds aimed at molecular targets.

Among the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of 44.6% of the neurogenomics market. The large market share of this segment is attributed to pharmaceutical & biotechnology companies' increasing R&D spending and the rising incidence of neurological diseases, which drives the adoption of advanced products among pharmaceutical & biotechnology companies.

Scope of the Report:

Neurogenomics Market Assessment-by Offering

• Next-generation Sequencing
  • Systems
  • Kits & Reagents
• DNA Extraction & Amplification Kits & Reagents
• Library Preparation & Target Enrichment Kits & Reagents
• Quality Control Kits & Reagents
  • Other Kits & Reagents
• Polymerase Chain Reaction (PCR)
  • Systems
  • Kits & Reagents
• Microarray
  • Readers & Scanners
  • Kits & Reagents
• DNA & RNA Microarray Kits & Reagents
• Protein Microarray Kits & Reagents
• Tissue Microarray Kits & Reagents
• Software & Services

Neurogenomics Market Assessment-by Application

• Research Applications
  • Target Identification
  • Functional Studies
  • Variant Discovery
  • Transcription Factor Binding Analysis
• Clinical Applications

Neurogenomics Market Assessment-by End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospitals & Diagnostic Laboratories

Neurogenomics Market Assessment-by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • U.K.
  • Spain
  • Rest of Europe (RoE)
• Asia-Pacific
  • China
  • Japan
  • India
  • Rest of Asia-Pacific (RoAPAC)
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition and Scope
• 1.2. Market Ecosystem
• 1.3. Currency & Limitation
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Data Collection and Validation Process
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
• 2.3. Market Sizing and Forecast
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Market Share Analysis
  • 2.3.3. Growth Forecast Approach
• 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Factors Affecting Market Growth
  • 4.2.1. Impact Analysis of Market Dynamics
  • 4.2.2. Factor Analysis
• 4.3. Pricing Analysis
• 4.4. Technology Trends
  • 4.4.1. Development of Portable Sequencing Technologies
• 4.5. Regulatory Analysis
  • 4.5.1. Neurogenomics Instruments & Consumables
    • 4.5.1.1. North America
      • 4.5.1.1.1. U.S.
      • 4.5.1.1.2. Canada
    • 4.5.1.2. Europe
    • 4.5.1.3. Asia-Pacific
      • 4.5.1.3.1. China
      • 4.5.1.3.2. Japan
      • 4.5.1.3.3. India
    • 4.5.1.4. Latin America
    • 4.5.1.5. Middle East
  • 4.5.2. Neurogenomics Software
• 4.6. Porter's Five Forces Analysis

5. Neurogenomics Market Assessment-by Offering

• 5.1. Overview
• 5.2. Next-generation Sequencing (NGS)
  • 5.2.1. Kits & Reagents
    • 5.2.1.1. Library Preparation & Target Enrichment Kits & Reagents
    • 5.2.1.2. DNA Extraction and Amplification Kits & Reagents
    • 5.2.1.3. Quality Control Kits & Reagents
    • 5.2.1.4. Other Kits & Reagents
  • 5.2.2. Systems
• 5.3. Polymerase Chain Reaction (PCR)
  • 5.3.1. Kits & Reagents
  • 5.3.2. Systems
• 5.4. Microarray
  • 5.4.1. Kits & Reagents
    • 5.4.1.1. DNA & RNA Microarray Kits & Reagents
    • 5.4.1.2. Protein Microarray Kits & Reagents
    • 5.4.1.3. Tissue Microarray Kits & Reagents
  • 5.4.2. Readers & Scanners
• 5.5. Software & Services

6. Neurogenomics Market Assessment-by Application

• 6.1. Overview
• 6.2. Research Applications
  • 6.2.1. Target Identification
  • 6.2.2. Functional Studies
  • 6.2.3. Variant Discovery
  • 6.2.4. Transcription Factor Binding Analysis
• 6.3. Clinical Applications

7. Neurogenomics Market Assessment-by End User

• 7.1. Overview
• 7.2. Pharmaceutical & Biotechnology Companies
• 7.3. Academic & Research Institutes
• 7.4. Hospitals & Diagnostic Laboratories

8. Neurogenomics Market Assessment-by Geography

• 8.1. Overview
• 8.2. North America
  • 8.2.1. U.S.
  • 8.2.2. Canada
• 8.3. Europe
  • 8.3.1. Germany
  • 8.3.2. France
  • 8.3.3. U.K.
  • 8.3.4. Italy
  • 8.3.5. Spain
  • 8.3.6. Rest of Europe (RoE)
• 8.4. Asia-Pacific
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Rest of Asia-Pacific (RoAPAC)
• 8.5. Latin America
• 8.6. Middle East & Africa

9. Competition Analysis

• 9.1. Overview
• 9.2. Key Growth Strategies
• 9.3. Competitive Benchmarking
• 9.4. Competitive Dashboard
  • 9.4.1. Industry Leaders
  • 9.4.2. Market Differentiators
  • 9.4.3. Vanguards
  • 9.4.4. Emerging Companies
• 9.5. Market Share Analysis (2023)
  • 9.5.1. Illumina, Inc. (U.S.)
  • 9.5.2. Thermo Fisher Scientific Inc. (U.S.)
  • 9.5.3. F. Hoffmann-La Roche Ltd (Switzerland)

10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)

• 10.1. Illumina, Inc.
• 10.2. Thermo Fisher Scientific Inc.
• 10.3. F. Hoffmann-La Roche Ltd
• 10.4. Agilent Technologies, Inc.
• 10.5. MGI Tech Co., Ltd.
• 10.6. QIAGEN N.V.
• 10.7. Revvity, Inc.
• 10.8. Pacific Biosciences of California Inc.
• 10.9. Danaher Corporation
• 10.10. Oxford Nanopore Technologies Plc.

(Note: *SWOT Analysis of the top 5 companies will be provided)

11. Appendix

• 11.1. Available Customization
• 11.2. Related Reports